4.48
-0.28
(-5.88%)
Real-time:
12:10PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.47 - 4.80 |
| 52 week | 4.47 - 37.19 |
| Open | 4.59 |
| Vol / Avg. | 3.61M/5.84M |
| Mkt cap | 689.89M |
| P/E | - |
| Div/yield | - |
| EPS | -2.10 |
| Shares | 153.99M |
| Beta | 3.88 |
| Inst. own | 64% |
Events
Aug 15, 2012
Dendreon Corporation at Canaccord Genuity's Global Growth Conference
- 4:00PM EDT -
Jul 30, 2012
Q2 2012 Dendreon Corporation Earnings Conference Call
Jun 26, 2012
Dendreon Corporation at The NASDAQ OMX Group, Inc. INVESTOR PROGRAM
Jun 13, 2012
Dendreon Corporation Annual Shareholder Meeting
Jun 5, 2012
Dendreon Corporation at Goldman Sachs Healthcare Conference
Jun 4, 2012
Dendreon Corporation at Jefferies Global Healthcare Conference
Jun 4, 2012
Dendreon Corporation at American Society of Clinical Oncology Annual Meeting
Jun 3, 2012
Dendreon Corporation at American Society of Clinical Oncology Annual Meeting
May 16, 2012
Dendreon Corporation at Bank of America Merrill Lynch Health Care Conference
May 9, 2012
Dendreon Corporation at Robert W Baird's Growth Stock Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | -120.18% | -98.89% |
| Operating margin | -103.45% | -85.39% |
| EBITD margin | - | -74.65% |
| Return on average assets | - | -42.08% |
| Return on average equity | - | -79.92% |
| Employees | 1,475 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 3200, 1301 2nd Avenue
SEATTLE, WA 98101
United States - Map
+1-206-2564545 (Phone)
+1-206-2560571 (Fax)
SEATTLE, WA 98101
United States - Map
+1-206-2564545 (Phone)
+1-206-2560571 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon�s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates it has under development include investigational cellular immunotherapies targeted towards HER2/neu, carbonic anhydrase 9 (CA9) and carcinoembryonic antigen (CEA).
Officers and directors
| John H. Johnson | Chairman of the Board, President, Chief Executive Officer | |
| Gregory T. Schiffman | Chief Financial Officer, Executive Vice President, Treasurer | |
| David L. Urdal Ph.D. | Executive Vice President, Chief Scientific Officer, Director | |
| Christine Mikail Cvijic | Executive Vice President - Corporate Development, General Counsel, Secretary | |
| Joseph I. DePinto | Executive Vice President - Global Commercial Operations | |
| Mark W. Frohlich M.D. | Executive Vice President - Research and Development and Chief Medical Officer | |
| Robert S. Poulton | Executive Vice President - Technical Operations | |
| Richard J. Ranieri | Executive Vice President - Human Resources | |
| Douglas G. Watson | Lead Independent Director | |
| Mitchell H. Gold M.D. | Director |